A handful of nanomaterials are being studied in clinical trials or have already been approved by the FDA for use in humans and many proof-of-concept studies of nanomaterials in cell-culture and small-animal models for medical applications are under way.
Many of these nanomaterials are designed to target tumors in vivo and are intended for use either as drug ...............